《Table 3The second infusion of CAR T cells and patient outcomes.》
提示:宽带有限、当前游客访问压缩模式
本系列图表出处文件名:随高清版一同展现
《供体来源的CD19靶向T细胞输注消除异基因造血干细胞移植后对供者淋巴细胞无反应的急性B淋巴细胞白血病微小残留病》
One patient required medication intervention(tocilizumab):Patient 6 developed a rash,fever,and hypotension on the 8thday after infusion and received two doses of tocilizumab on the 8th and 9th days after infusion.
图表编号 | XD0061018600 严禁用于非法目的 |
---|---|
绘制时间 | 2019.02.01 |
作者 | 程翼飞、陈育红、闫晨华、王昱、赵翔宇、陈瑶、韩伟、许兰平、张晓辉、刘开彦、王莎莎、张隆基、肖磊、黄晓军 |
绘制单位 | Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Peking University Institute of Hematology,Peking University People's Hospital、Collaborative Innovation Center of Hematology,Peking University、Beijing Key Laboratory of Hematopoietic Stem C |
更多格式 | 高清、无水印(增值服务) |